Deal covers use of ZFN technology for the generation of transgenic animals.

Sigma-Aldrich and Sangamo BioSciences are giving Roche nonexclusive, worldwide rights to use its zinc finger nuclease (ZFN) technology. Roche will use this platform to develop cell lines and transgenic animals that have targeted modifications in a specified gene in particular species.

Under this research and license agreement, Roche also has an option to obtain an exclusive, worldwide license for the commercial use of such ZFN-generated transgenic animals in the production of therapeutic and diagnostic products.

The research phase of the agreement will be conducted in collaboration with Sangamo and Sigma-Aldrich, Sangamo’s exclusive licensee of ZFN technology for high-value research reagents.

Previous articleGlobeImmune Receives Support from NCI to Advance Tarmogen Technology
Next articleLilly to Pay $64M for SGX Pharmaceuticals